1. Home
  2. SDGR vs IOVA Comparison

SDGR vs IOVA Comparison

Compare SDGR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

N/A

Current Price

$30.46

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$14.23

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SDGR
IOVA
Founded
1990
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
SDGR
IOVA
Price
$30.46
$14.23
Analyst Decision
Buy
Buy
Analyst Count
7
10
Target Price
★ $21.43
$10.70
AVG Volume (30 Days)
2.0M
★ 12.3M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 45.14
14.84
EPS
N/A
★ N/A
Revenue
★ $255,869,000.00
N/A
Revenue This Year
N/A
$54.93
Revenue Next Year
$3.12
$40.91
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 23.29
N/A
52 Week Low
$10.95
$1.76
52 Week High
$31.59
$15.06

Technical Indicators

Market Signals
Indicator
SDGR
IOVA
Relative Strength Index (RSI) 73.76 86.63
Support Level $11.27 $3.57
Resistance Level $31.59 N/A
Average True Range (ATR) 2.33 0.65
MACD 0.28 0.45
Stochastic Oscillator 90.69 95.63

Price Performance

Historical Comparison
SDGR
IOVA

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: